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I
tisnow10yearssincethelasttechnical
review on preventative foot care was
published (1), which was followed by
an American Diabetes Association (ADA)
positionstatementonpreventivefootcare
in diabetes (2). Many studies have been
published proposing a range of tests that
might usefully identify patients at risk of
footulceration,creatingconfusionamong
practitioners as to which screening tests
should be adopted in clinical practice. A
task force was therefore assembled by the
ADA to address and concisely summarize
recent literature in this area and then rec-
ommend what should be included in the
comprehensive foot exam for adult pa-
tients with diabetes. The committee was
cochaired by the immediate past and cur-
rent chairs of the ADA Foot Care Interest
Group (A.J.M.B. and D.G.A.), with other
panel members representing primary
care, orthopedic and vascular surgery,
physical therapy, podiatric medicine and
surgery, and the American Association of
Clinical Endocrinologists.
THE PATHWAY TO FOOT
ULCERATION
Thelifetimeriskofapersonwithdiabetes
developing a foot ulcer may be as high as
25%, whereas the annual incidence of
foot ulcers is 2% (3–7). Up to 50% of
older patients with type 2 diabetes have
oneormoreriskfactorsforfootulceration
(3,6). A number of component causes,
most importantly peripheral neuropathy,
interacttocompletethecausalpathwayto
foot ulceration (1,3–5). A list of the prin-
cipal contributory factors that might re-
sultinfootulcerdevelopmentisprovided
in Table 1.
The most common triad of causes
that interact and ultimately result in ul-
ceration has been identiﬁed as neuropa-
thy, deformity, and trauma (5). As
identiﬁcation of those patients at risk of
foot problems is the ﬁrst step in prevent-
ing such complications, this report will
focus on key components of the foot
exam.
COMPONENTS OF THE
FOOT EXAM
History
While history is a pivotal component of
risk assessment, a patient cannot be fully
assessedforriskfactorsforfootulceration
based on history alone; a careful foot
exam remains the key component of this
process. Key components of the history
includepreviousfootulcerationorampu-
tation. Other important assessments in
the history (Table 2) include neuropathic
or peripheral vascular symptoms (7,8),
impaired vision, or renal replacement
therapy. Lastly, tobacco use should be re-
corded, since cigarette smoking is a risk
factor not only for vascular disease but
also for neuropathy.
General inspection
Acarefulinspectionofthefeetinawell-lit
room should always be carried out after
the patient has removed shoes and socks.
Because inappropriate footwear and foot
deformities are common contributory
factors in the development of foot ulcer-
ation (1,5), the shoes should be inspected
and the question “Are these shoes appro-
priate for these feet?” should be asked.
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Table 1—Risk factors for foot ulcers
• Previous amputation
• Past foot ulcer history
• Peripheral neuropathy
• Foot deformity
• Peripheral vascular disease
• Visual impairment
• Diabetic nephropathy (especially patients
on dialysis)
• Poor glycemic control
• Cigarette smoking
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those that are excessively worn or are too
smallfortheperson’sfeet(toonarrow,too
short, toe box too low), resulting in rub-
bing,erythema,blister,orcallus.Features
that should be assessed during foot in-
spection are outlined in Table 3 and are
discussed below.
Dermatological assessment. The der-
matological assessment should initially
include a global inspection, including in-
terdigitally, for the presence of ulceration
or areas of abnormal erythema. The pres-
ence of callus (particularly with hemor-
rhage), nail dystrophy, or paronychia
should be recorded (9), with any of these
ﬁndings prompting referral to a specialist
or specialty clinic. Focal or global skin
temperature differences between one foot
and the other may be predictive of either
vascular disease or ulceration and could
alsopromptreferralforspecialtyfootcare
(10–13).
Musculoskeletal assessment. The mus-
culoskeletal assessment should include
evaluation for any gross deformity (14).
Rigid deformities are deﬁned as any con-
tractures that cannot easily be manually
reduced and are most frequently found in
the digits. Common forefoot deformities
that are known to increase plantar pres-
sures and are associated with skin break-
down include metatarsal phalangeal joint
hyperextensionwithinterphalangealﬂex-
ion (claw toe) or distal phalangeal exten-
sion (hammer toe) (15–17). (Examples of
these deformities are shown in Fig. 1.)
An important and often overlooked
or misdiagnosed condition is Charcot ar-
thropathy.Thisoccursintheneuropathic
foot and most often affects the midfoot.
This may present as a unilateral red, hot,
swollen, ﬂat foot with profound defor-
mity (18–20). A patient with suspected
Charcot arthropathy should be immedi-
ately referred to a specialist for further
assessment and care.
Neurological assessment
Peripheral neuropathy is the most com-
mon component cause in the pathway to
diabetic foot ulceration (1,4,5,7). The
clinical exam recommended, however, is
designedtoidentifylossofprotectivesen-
sation (LOPS) rather than early neuropa-
thy. The diagnosis and management of
the latter were covered in a 2004 ADA
technical review (7). The clinical exami-
nation to identify LOPS is simple and re-
quires no expensive equipment.
Five simple clinical tests (Table 3),
each with evidence from well-conducted
prospective clinical cohort studies, are
considered useful in the diagnosis of
LOPS in the diabetic foot (1–7). The task
force agrees that any of the ﬁve tests listed
could be used by clinicians to identify
LOPS, although ideally two of these
should be regularly performed during the
screening exam—normally the 10-g
monoﬁlament and one other test. One or
more abnormal tests would suggest
LOPS,whileatleasttwonormaltests(and
no abnormal test) would rule out LOPS.
The last test listed, vibration assessment
using a biothesiometer or similar instru-
ment,iswidelyusedintheU.S.;however,
identiﬁcation of the patient with LOPS
can easily be carried out without this or
other expensive equipment.
10-g monoﬁlaments. Monoﬁlaments,
sometimes known as Semmes-Weinstein
monoﬁlaments, were originally used to
diagnose sensory loss in leprosy (21).
Many prospective studies have conﬁrmed
that loss of pressure sensation using the
10-g monoﬁlament is highly predictive of
subsequent ulceration (3,21,22). Screen-
ing for sensory loss with the 10-g mono-
ﬁlament is in widespread use across the
world, and its efﬁcacy in this regard has
been conﬁrmed in a number of trials, in-
cluding the recent Seattle Diabetic Foot
Study (4,21,23,24).
Nylon monoﬁlaments are con-
structed to buckle when a 10-g force is
applied; loss of the ability to detect this
pressure at one or more anatomic sites on
the plantar surface of the foot has been
associated with loss of large-ﬁber nerve
function. It is recommended that four
sites (1st, 3rd, and 5th metatarsal heads
and plantar surface of distal hallux) be
tested on each foot.
The technique for testing pressure
perceptionwiththe10-gmonoﬁlamentis
illustrated in Fig. 2; patients should close
their eyes while being tested. Caution is
necessary when selecting the brand of
monoﬁlament to use, as many commer-
cially available monoﬁlaments have been
shown to be inaccurate. Single-use dis-
posablemonoﬁlamentsorthoseshownto
be accurate by the Booth and Young (23)
studyarerecommended.Thesensationof
pressure using the buckling 10-g mono-
ﬁlament should ﬁrst be demonstrated to
the patient on a proximal site (e.g., upper
arm). The sites of the foot may then be
examined by asking the patient to re-
spond “yes” or “no” when asked whether
the monoﬁlament is being applied to the
particular site; the patient should recog-
nize the perception of pressure as well as
identify the correct site. Areas of callus
should always be avoided when testing
for pressure perception.
128-Hz tuning forks. The tuning fork is
widely used in clinical practice and pro-
vides an easy and inexpensive test of vi-
bratory sensation. Vibratory sensation
Table 2—Essential features of history
Past history
• ulceration
• amputation
• Charcot joint
• vascular surgery
• angioplasty
• cigarette smoking
Neuropathic symptoms
• positive (e.g., burning or shooting
pain, electrical or sharp sensations,
etc.)
• negative (e.g., numbness, feet feel
dead)
Vascular symptoms
• claudication
• rest pain
• nonhealing ulcer
Other diabetes complications
• renal (dialysis, transplant)
• retinal (visual impairment)
Table3—Keycomponentsofthediabeticfoot
exam
Inspection
Dermatologic
• skin status: color, thickness, dryness,
cracking
• sweating
• infection: check between toes for
fungal infection
• ulceration
• calluses/blistering: hemorrhage into
callus?
Musculoskeletal
• deformity, e.g., claw toes, prominent
metatarsal heads, Charcot joint (Fig. 1)
• muscle wasting (guttering between
metatarsals)
Neurological assessment
10-g monoﬁlament  1 of the following 4
• vibration using 128-Hz tuning fork
• pinprick sensation
• ankle reﬂexes
• VPT
Vascular assessment
• foot pulses
• ABI, if indicated
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toe bilaterally. An abnormal response can
be deﬁned as when the patient loses vi-
bratory sensation and the examiner still
perceives it while holding the fork on the
tip of the toe (3,4).
Pinprick sensation. Similarly, the in-
ability of a subject to perceive pinprick
sensation has been associated with an in-
creased risk of ulceration (4). A dispos-
able pin should be applied just proximal
to the toenail on the dorsal surface of the
hallux, with just enough pressure to de-
form the skin. Inability to perceive pin-
prick over either hallux would be
regarded as an abnormal test result.
Ankle reﬂexes. Absence of ankle re-
ﬂexes has also been associated with in-
creased risk of foot ulceration (4). Ankle
reﬂexes can be tested with the patient ei-
ther kneeling or resting on a couch/table.
The Achilles tendon should be stretched
until the ankle is in a neutral position be-
forestrikingitwiththetendonhammer.If
a response is initially absent, the patient
can be asked to hook ﬁngers together and
pull, with the ankle reﬂexes then retested
with reinforcement. Total absence of an-
kle reﬂex either at rest or upon reinforce-
ment is regarded as an abnormal result.
Vibrationperceptionthresholdtesting.
The biothesiometer (or neurothesiom-
eter) is a simple handheld device that
gives semiquantitative assessment of vi-
bration perception threshold (VPT). As
for vibration using the 128-Hz tuning
fork, vibration perception using the
biothesiometerisalsotestedoverthepulp
of the hallux. With the patient lying su-
Figure1—Footdeformities.Thesesitesarefrequentlocationsfordiabeticfootulceration.A:Clawtoedeformity.Notethebucklingphenomenonthat
causes increased pressure on the dorsal hammer digit deformity, as well as on the plantar metatarsal head. B: Bunion and overlapping toes. This
deformity can lead to pressure ulceration between the digits, on the dorsal or plantar surfaces of displaced digits, and over the medial ﬁrst
metatarsophalangeal joint. C: A rocker-bottom deformity secondary to Charcot arthropathy can cause excessive pressure at the plantar midfoot,
increasing risk for ulceration at that site.
Boulton and Associates
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over the dorsal hallux and the amplitude
is increased until the patient can detect
the vibration; the resulting number is
known as the VPT. This process should
initially be demonstrated on a proximal
site, and then the mean of three readings
is taken over each hallux. A VPT 2 5Vi s
regarded as abnormal and has been
shown to be strongly predictive of subse-
quent foot ulceration (15,22).
Vascular assessment
Peripheralarterialdisease(PAD)isacom-
ponent cause in approximately one-third
offootulcersandisoftenasigniﬁcantrisk
factor associated with recurrent wounds
(5,25). Therefore, the assessment of PAD
is important in deﬁning overall lower-
extremity risk status. Vascular examina-
tion should include palpation of the
posterior tibial and dorsalis pedis pulses
(10,26),whichshouldbecharacterizedas
either “present” or “absent” (26).
Diabetic patients with signs or symp-
toms of vascular disease (Table 2) or ab-
sentpulsesonscreeningfootexamination
should undergo ankle brachial pressure
index (ABI) pressure testing and be con-
sideredforapossiblereferraltoavascular
specialist. The ABI is a simple and easily
reproducible method of diagnosing vas-
cular insufﬁciency in the lower limbs.
Bloodpressureattheankle(dorsalispedis
or posterior tibial arteries) is measured
using a standard Doppler ultrasonic
probe. This technique is outlined in Fig.
3. The ABI is obtained by dividing the
ankle systolic pressure by the higher of
thetwobrachialsystolicpressures(8).An
ABI 0.9 is normal, 0.8 is associated
withclaudication,and0.4iscommonly
associated with ischemic rest pain and
tissue necrosis.
The ADA Consensus Panel on PAD
recommended measurement of ABI in di-
abetic patients over 50 years of age and
consideration of ABI measurement in
younger patients with multiple PAD risk
factors, repeating normal tests every 5
years(8).ABImaythereforebepartofthe
annual comprehensive foot exam in these
patient subgroups. ABI measurements
maybemisleadingindiabetesbecausethe
presence of medial calcinosis renders the
arteries incompressible and results in
falsely elevated or supra-systolic ankle
Figure 2—Upper panel: For performance of the 10-g monoﬁlament test, the device is placed perpendicular to the skin, with pressure applied until
the monoﬁlament buckles. It should be held in place for 1 s and then released. Lower panel: The monoﬁlament test should be performed at the
highlighted sites while the patient’s eyes are closed.
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ible calf or ankle arteries (ABI 1.3),
measurements of digital arterial systolic
pressure (toe pressure) or transcutaneous
oxygen tension may be performed.
Risk classiﬁcation and referral/
follow-up
Once the patient has been thoroughly as-
sessed as described above, he or she
should be assigned to a foot risk category
(Table 4). These categories are designed
to direct referral and subsequent therapy
by the specialty clinician or team (17,20)
and frequency of follow-up by the gener-
alistorspecialist.Increasedcategoryisas-
sociated with an increased risk for
ulceration, hospitalization, and amputa-
tion (17). Patients in risk category 0 gen-
erally do not need referral and should
receive general foot care education and
undergo comprehensive foot examina-
tion annually. Patients in foot risk cate-
gory 1 may be managed by a generalist or
specialist every 3–6 months. Consider-
ation should be given to an initial special-
ist referral to assess the need for
specialized treatment and follow-up.
Those in categories 2 and 3 should be re-
ferred to a foot care specialist or specialty
clinic and seen every 1–3 months.
CONCLUSIONS — It cannot be over-
stated that the complications of the dia-
betic foot are common, complex, and
costly, mandating aggressive and proac-
tive preventative assessments by general-
ists and specialists. All patients with
diabetes must have their feet evaluated at
least at yearly intervals for the presence of
the predisposing factors for ulceration
and amputation (neuropathy, vascular
disease, and deformities). This report
summarizes a simple protocol for doing
so. If abnormalities are present, more fre-
quent evaluation of the diabetic foot is
recommended depending on risk cate-
gory, as described above and in Table 4.
Figure 3—Lower-extremity circulation and the ABI test. A: Anterior view, right lower limb, normal arterial anatomy. B: ABI. Place blood pressure
cuff above pulse. Place Doppler probe over arterial pulse; a: posterior tibial artery, b: dorsalis pedis artery. ABI calculation: Divide ankle systolic
blood pressure by brachial artery systolic blood pressure. (ABI 0.9 is normal.) Adapted from Khan et al., JAMA 295:536–546, 2006.
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and risk assessment, patient education,
and timely referral that we may further
reduce the unnecessarily high preva-
lenceoflower-extremitymorbidityinthis
population.
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